Signal Transduction And Targeted Therapy

Signal Transduction And Targeted Therapy

信号转导与靶向治疗

  • 1区 中科院分区
  • Q1 JCR分区

期刊简介

《Signal Transduction And Targeted Therapy》是由Springer Nature出版社于2016年创办的英文国际期刊(ISSN: 2095-9907,E-ISSN: 2059-3635),该期刊长期致力于生化与分子生物学领域的创新研究,主要研究方向为Biochemistry, Genetics and Molecular Biology-Genetics。作为SCIE收录期刊(JCR分区 Q1,中科院 1区),本刊采用OA开放获取模式(OA占比1%),以发表生化与分子生物学领域等方向的原创性研究为核心(研究类文章占比60.29%%)。凭借严格的同行评审与高效编辑流程,期刊年载文量精选控制在272篇,确保学术质量与前沿性。成果覆盖Web of Science、Scopus等国际权威数据库,为学者提供推动医学领域高水平交流平台。

投稿咨询

投稿提示

Signal Transduction And Targeted Therapy审稿周期约为 5 Weeks 。该刊近年未被列入国际预警名单,年发文量约272篇,录用竞争适中,主题需确保紧密契合医学前沿。投稿策略提示:避开学术会议旺季投稿以缩短周期,语言建议专业润色提升可读性。

  • 医学 大类学科
  • English 出版语言
  • 是否预警
  • SCIE 期刊收录
  • 272 发文量

中科院分区

中科院 SCI 期刊分区 2023年12月升级版

Top期刊 综述期刊 大类学科 小类学科
医学
1区
BIOCHEMISTRY & MOLECULAR BIOLOGY 生化与分子生物学 CELL BIOLOGY 细胞生物学
1区 1区

中科院 SCI 期刊分区 2022年12月升级版

Top期刊 综述期刊 大类学科 小类学科
医学
1区
BIOCHEMISTRY & MOLECULAR BIOLOGY 生化与分子生物学 CELL BIOLOGY 细胞生物学
1区 1区

JCR分区

按JIF指标学科分区 收录子集 分区 排名 百分位
学科:BIOCHEMISTRY & MOLECULAR BIOLOGY SCIE Q1 3 / 313

99.2%

学科:CELL BIOLOGY SCIE Q1 5 / 205

97.8%

按JCI指标学科分区 收录子集 分区 排名 百分位
学科:BIOCHEMISTRY & MOLECULAR BIOLOGY SCIE Q1 5 / 313

98.56%

学科:CELL BIOLOGY SCIE Q1 6 / 205

97.32%

CiteScore

CiteScore SJR SNIP CiteScore 排名
CiteScore:44.5 SJR:8.737 SNIP:5.308
学科类别 分区 排名 百分位
大类:Biochemistry, Genetics and Molecular Biology 小类:Genetics Q1 2 / 347

99%

大类:Biochemistry, Genetics and Molecular Biology 小类:Cancer Research Q1 5 / 230

98%

期刊发文

  • Intranasal booster using an Omicron vaccine confers broad mucosal and systemic immunity against SARS-CoV-2 variants

    Author: Wang, Qian; Yang, Chenchen; Yin, Li; Sun, Jing; Wang, Wei; Li, Hengchun; Zhang, Zhengyuan; Chen, Si; Liu, Bo; Liu, Zijian; Shi, Linjing; Liu, Xiaolin; Guan, Suhua; Wang, Chunhua; Qu, Linbing; Feng, Ying; Niu, Xuefeng; Feng, Liqiang; Zhao, Jincun; Li, Pingchao; Chen, Ling; Zhong, Nanshan

    Journal: SIGNAL TRANSDUCTION AND TARGETED THERAPY. 2023; Vol. 8, Issue 1, pp. -. DOI: 10.1038/s41392-023-01423-6

  • Tumor heterogeneity in VHL drives metastasis in clear cell renal cell carcinoma

    Author: Hu, Junhui; Tan, Ping; Ishihara, Moe; Bayley, Nicholas A.; Schokrpur, Shiruyeh; Reynoso, Jeremy G.; Zhang, Yangjun; Lim, Raymond J.; Dumitras, Camelia; Yang, Lu; Dubinett, Steven M.; Jat, Parmjit S.; Van Snick, Jacques; Huang, Jiaoti; Chin, Arnold I.; Prins, Robert M.; Graeber, Thomas G.; Xu, Hua; Wu, Lily

    Journal: SIGNAL TRANSDUCTION AND TARGETED THERAPY. 2023; Vol. 8, Issue 1, pp. -. DOI: 10.1038/s41392-023-01362-2

  • Combination therapy with saxagliptin and vitamin D for the preservation of beta-cell function in adult-onset type 1 diabetes: a multi-center, randomized, controlled trial

    Author: Yan, Xiang; Li, Xia; Liu, Bingwen; Huang, Jiaqi; Xiang, Yufei; Hu, Yuhang; Tang, Xiaohan; Zhang, Ziwei; Huang, Gan; Xie, Zhiguo; Zhou, Houde; Liu, Zhenqi; Wang, Xiangbing; Leslie, Richard David; Zhou, Zhiguang

    Journal: SIGNAL TRANSDUCTION AND TARGETED THERAPY. 2023; Vol. 8, Issue 1, pp. -. DOI: 10.1038/s41392-023-01369-9

  • Signaling pathways in vascular function and hypertension: molecular mechanisms and therapeutic interventions

    Author: Ma, Jun; Li, Yanan; Yang, Xiangyu; Liu, Kai; Zhang, Xin; Zuo, Xianghao; Ye, Runyu; Wang, Ziqiong; Shi, Rufeng; Meng, Qingtao; Chen, Xiaoping

    Journal: SIGNAL TRANSDUCTION AND TARGETED THERAPY. 2023; Vol. 8, Issue 1, pp. -. DOI: 10.1038/s41392-023-01430-7

  • RBM4 dictates ESCC cell fate switch from cellular senescence to glutamine-addiction survival through inhibiting LKB1-AMPK-axis

    Author: Chen, Lei; Zhang, Wenjing; Chen, Dan; Yang, Quan; Sun, Siwen; Dai, Zhenwei; Li, Zhengzheng; Liang, Xuemei; Chen, Chaoqun; Jiao, Yuexia; Zhi, Lili; Zhao, Lianmei; Zhang, Jinrui; Liu, Xuefeng; Zhao, Jinyao; Li, Man; Wang, Yang; Qi, Yangfan

    Journal: SIGNAL TRANSDUCTION AND TARGETED THERAPY. 2023; Vol. 8, Issue 1, pp. -. DOI: 10.1038/s41392-023-01367-x

  • Preventive and therapeutic benefits of nelfinavir in rhesus macaques and human beings infected with SARS-CoV-2

    Author: Xu, Zhijian; Shi, Danrong; Han, Jian-Bao; Ling, Yun; Jiang, Xiangrui; Lu, Xiangyun; Li, Chuan; Gong, Likun; Ge, Guangbo; Zhang, Yani; Zang, Yi; Song, Tian-Zhang; Feng, Xiao-Li; Tian, Ren-Rong; Ji, Jia; Zhu, Miaojin; Wu, Nanping; Wu, Chunhui; Wang, Zhen; Xu, Yechun; Peng, Cheng; Zheng, Min; Yang, Junling; Du, Feifei; Wu, Junliang; Wang, Peipei; Shen, Jingshan; Zhang, Jianliang; Zheng, Yong-Tang; Yao, Hangping; Zhu, Weiliang

    Journal: SIGNAL TRANSDUCTION AND TARGETED THERAPY. 2023; Vol. 8, Issue 1, pp. -. DOI: 10.1038/s41392-023-01429-0

  • Targeting integrin pathways: mechanisms and advances in therapy

    Author: Pang, Xiaocong; He, Xu; Qiu, Zhiwei; Zhang, Hanxu; Xie, Ran; Liu, Zhiyan; Gu, Yanlun; Zhao, Nan; Xiang, Qian; Cui, Yimin

    Journal: SIGNAL TRANSDUCTION AND TARGETED THERAPY. 2023; Vol. 8, Issue 1, pp. -. DOI: 10.1038/s41392-022-01259-6

  • SCGN deficiency is a risk factor for autism spectrum disorder

    Author: Liu, Zhe; Tan, Shuai; Zhou, Lianyu; Chen, Li; Liu, Mingfeng; Wang, Wang; Tang, Yingying; Yang, Qin; Chi, Sensen; Jiang, Peiyan; Zhang, Yue; Cui, Yonghua; Qin, Junhong; Hu, Xiao; Li, Shenglong; Liu, Qi; Chen, Lu; Li, Song; Burstein, Ezra; Li, Wei; Zhang, Xiaohu; Mo, Xianming; Jia, Da

    Journal: SIGNAL TRANSDUCTION AND TARGETED THERAPY. 2023; Vol. 8, Issue 1, pp. -. DOI: 10.1038/s41392-022-01225-2